https://orcid.org/0000-0002-5559-6847
References
- Barnes, P. J., S. J. Pocock, H. Magnussen, A. Iqbal, B. Kramer, M. Higgins, and D. Lawrence. 2010. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulmonary Pharmacology & Therapeutics 23 (3):165–171. doi:10.1016/j.pupt.2010.01.003.
- Bhatt, D. L., and C. Mehta. 2016. Adaptive designs for clinical trials. New England Journal of Medicine 375 (1):65–74. doi:10.1056/NEJMra1510061.
- Chen, Y. J., R. Gesser, and A. Luxembourg. February 1, 2015. A seamless phase IIB/III adaptive outcome 1272 trial: design rationale and implementation challenges. Clinical Trials 12 (1):84–90. doi: 10.1177/1740774514566333.
- Chow, S. C., and M. Chang. 2011. Adaptive design methods in clinical trials. Chapman and Hall/CRC, New York, NY
- Chow, S. C., and M. Lin. 2015. Analysis of two-stage adaptive seamless trial design. Pharmaceutica Analytica Acta 6:3. doi:10.4172/2153-2435.1000341.
- Food and Drug Administration. 2010. Guidance for industry: adaptive design clinical trials for drugs and biologics. Washington DC, USA: Food and Drug Administration.
- Food and Drug Administration. 2018. Guidance for industry: adaptive design clinical trials for drugs and biologics [Draft guidance]. FDA website: https://www.fda.gov/downloads/drugs/guidances/ucm201790.pdf
- Lawrence, D., F. Bretz, and S. J. Pocock. 2014. Indacaterol. In INHANCE: an adaptive confirmatory study with dose selection at interim, ed. A. Trifilieff, 77–92. Basel, Switzerland: Springer Basel.
- Lee, S. J., and M. Lin. 2016. Adaptive trial design – case studies. Presented at the 2016 Duke-Industry Statistics Symposium (DISS), Durham, North Carolina, September 14.